CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

216395Orig1s000

PRODUCT QUALITY REVIEW(S)

Title:	NDA IQA Template Title Page- EXEC SUMMARY
Document ID:	OPQ-ALL-TEM-0040
Effective Date:	26 Sep 2023 Revision: 00
Total Pages:	5

Template Revision: 03

Office of Pharmaceutical Quality

New Drug Application (NDA)
Integrated Quality Assessment Template

NDA Executive Summary

1. Application/Product Information

NDA Number	216395
Applicant Name	CMP Development LLC
Drug Product Name	QUIOFIC (folic acid) oral solution
Dosage Form	Solution
Proposed Strength(s)	1 mg/5 mL (0.2 mg/mL)
NDA Classification	Type 3 - New Dosage Form
Route of Administration	Oral
Maximum Daily Dose	1 mg
Rx/OTC Dispensed	Rx
Proposed Indication	For the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood.
Drug Product Description	CMP Development submitted this 505(b)(2) new drug application for QUIOFIC (folic acid) oral solution, 0.2 mg/mL. The drug product is indicated for the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or non-tropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. The drug product was designed to provide an alternative dosage form to Folic Acid Tablets for patients with dysphagia (difficulty swallowing). Folic acid is a B-complex vitamin that acts on megaloblastic bone marrow to produce a normoblastic marrow. The folic acid drug substance is stable in solid form. Because QUIOFIC Oral Solution is a liquid product [redacted] (b) (4) do not impact the manufacturing

	processing or the pharmacology of the finished product. QUIOFIC (folic acid) oral solution contains the active pharmaceutical ingredient folic acid (0.2 mg/mL) and the following inactive ingredients: edetate disodium, methylparaben, mixed berry flavor, propylene glycol, propylparaben, purified water, sodium phosphate dibasic, sodium phosphate monobasic, and sorbitol solution. (b) (4) The applicant conducted a comprehensive nitrosamine risk assessment (Report Number REP-0000037) for Folic Acid Oral Solution, 1 mg/5 mL (0.2 mg/mL) (b) (4) . From a CMC perspective, the risk of a nitrosamine drug substance-related impurity (NDSRI) being present in QUIOFIC (folic acid) oral solution is low (b) (4) QUIOFIC (folic acid) oral solution, 0.2 mg/mL is supplied in (b) (4) Amber PETE Bottles with (b) (4) White Child-Resistant Closures containing 75 mL. This drug product should be stored at 20° to 25°C (68° to 77°F).
Co-packaged product information	Not applicable
Device information	Not applicable
Storage Temperature/ Conditions	20ºC to 25ºC (68ºF to 77ºF)

Review Team	**Discipline**	**Primary**	**Secondary**
	Drug Substance	Mitchell McCloskey, PhD	Zhengfu Wang, PhD
	Drug Product/ Labeling	Parvin Akther, PhD	Richard Matsuoka, PhD
	Manufacturing	Vladimir Dragan, PhD	Feiyan Jin, PhD
	Biopharmaceutics	Not applicable	Not applicable
	Microbiology	Xia Xu, PhD	Yan Zheng, PhD
	Other (specify)		
	RBPM	Grafton Adams	
	ATL	Richard Matsuoka, PhD	
Consults	Not applicable		

2. Final Overall Recommendation - Approval

This applicant is recommended for approval from all OPQ review disciplines.

4. Basis for Recommendation:

a. Summary of Rationale for Recommendation:

- The applicant of this 505(b)(2) new drug application has provided sufficient CMC information to ensure the identity, strength, purity, and quality of the drug product QUIOFIC (folic acid) oral solution, 1 mg / 5 mL (0.2 mg/mL).
- The Office of Pharmaceutical Manufacturing Assessment (OPMA) has made the overall manufacturing inspection recommendation of "Approve" for the facilities involved in this application.
- The CMC recommended changes to the labeling have been communicated to the applicant through the Clinical Review Team, and the recommended CMC revisions have been accepted.
- The applicant's request for categorical exclusion from the preparation of an environmental assessment has been found adequate and is granted.

b. Is the overall recommendation in agreement with the individual discipline recommendations? Yes

Recommendation by Subdiscipline:

Drug Substance	**-**	**Adequate**
Drug Product	**-**	**Adequate**
Quality Labeling	**-**	**Adequate**
Manufacturing	**-**	**Adequate**
Biopharmaceutics	**-**	**N/A**
Microbiology	**-**	**Adequate**

Environmental Assessment: Categorical Exclusion - Adequate
QPA for EA(s): No

5. Life-Cycle Considerations

Established Conditions per ICH Q12: No
Comments:

Comparability Protocols (PACMP): No
Comments:

Additional Lifecycle Comments: None

Application Technical Lead Name and Date:

Richard Matsuoka, Ph.D.
Senior Pharmaceutical Quality Assessor
DPQA II / OPQA I / OPQ

69 Page(s) have been Withheld in Full as B4 (CCI/TS) immediately following this page

CHAPTER IV: LABELING

NDA Number	216395
Assessment Cycle Number	1
Drug Product (DP) Name	QUIOFIC® (folic acid) oral solution

Assessment Recommendation: Adequate

Item	Assessment Conclusion	SDN # where labeling is adequate ("N/A" otherwise)
Prescribing Information Labeling	Adequate	14
Patient Information	N/A	N/A
Instruction for Use (IFU)	N/A	N/A
Container Labels	Adequate	14
Carton Labeling	N/A	N/A

Brief Description of Outstanding Issues:

Submissions being reviewed:

Document Reviewed (eCTD #, SDN #)	Date Received	Information Provided
(0001, 1) (0011, 11) (0014, 14)	03/26/2025 10/09/2025 11/19/2025	Prescribing Information Labeling and Container Labels
(0004, 4)	04/21/2025	Prescribing Information Labeling

1.0 PRESCRIBING INFORMATION[1]

Assessment of Product Quality Related Aspects of the Prescribing Information: Submitted on April 21, 2025 SDN 4 and Submitted on November 19, 2025 SDN 14

[1] Labeling Review Tool (LRT) (March 2022), including use of consistent terminology for dosage form and unit of measure for strength in the product title and DOSAGE FORMS AND STRENGTHS heading in Highlights, in the DOSAGE AND ADMINISTRATION, DOSAGE FORMS AND STRENGTHS, DESCRIPTION, and HOW SUPPLIED/STORAGE AND HANDLING sections (see page 2 of LRT)

1.1 HIGHLIGHTS OF PRESCRIBING INFORMATION

(b) (4)

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments (If an item is Inadequate, provide more details on the issues, as appropriate)
Product Title in Highlights[2] [21 CFR 201.57(a)(2)]		
Established name(s)[3]	Adequate	
Route(s) of administration	Adequate	
Controlled drug substance symbol (if applicable)	N/A	
Initial U.S. Approval [§201.57(a)(3)]	Adequate	
Dosage Forms and Strengths Heading in Highlights [§ 201.57(a)(8)]		
Dosage form(s)[4] and strength(s) in metric system[5]	Adequate	
If the drug product contains an active ingredient that is a salt, clearly state whether the strength is based on the active moiety (e.g., Tablets: 10 mg of drug-x) or active ingredient (e.g., Tablets: 10 mg of drug-x hydrochloride).[6]	N/A	

[2] Draft guidance: *Product Title and Initial U.S. Approval in the Highlights of Prescribing Information for Human Prescription Drug and Biological Products — Content and Format* (January 2018)
[3] Established name = [Drug] [Route of Administration] [Dosage Form]. Do use not "USP" descriptor in the product title or within the Highlights (see page 3 of LRT).
[4] Draft guidance: *Product Title and Initial U.S. Approval in the Highlights of Prescribing Information for Human Prescription Drug and Biological Products — Content and Format* (January 2018); USP <1151>; USP Nomenclature Guideline
[5] Labeling Review Tool (March 2022, page 13), include limited packaging information; USP <7>
[6] Guidance: *Naming of Drug Products Containing Salt Drug Substances* (June 2015); MAPP 5021.1

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments (If an item is Inadequate, provide more details on the issues, as appropriate)
Assess if the tablet is scored. If product meets guidelines and criteria for a scored tablet, state "functionally scored."[7]	N/A	
For injectable drug products for parenteral administration, use appropriate package type term (e.g., single-dose, multiple-dose, single-patient-use). Other package terms include pharmacy bulk package and imaging bulk package.[8]	N/A	

Assessment: *Adequate*

1.2 FULL PRESCRIBING INFORMATION

1.2.1 Section 2 (DOSAGE AND ADMINISTRATION)[9]

(b) (4)

[redacted]

[7] Guidance: *Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation* (March 2013)
[8] Guidance: *Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use* (October 2018); USP <659>
[9] See § 201.57(c)(3); draft guidance: *Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format* (January 2023); Labeling Review Tool (March 2022, page 25)

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments (If an item is Inadequate, provide more details on the issues, as appropriate)
DOSAGE AND ADMINISTRATION section		
Special instructions for product preparation (e.g., reconstitution and resulting concentration, dilution, compatible diluents and/or soft food[10], storage conditions needed to maintain the stability of the reconstituted or diluted product).	N/A	
Important administration instructions supported by product quality information (e.g., do not crush or chew extended-release tablets, instructions for mixing with food).	Inadequate	We recommend creating a new Section 2.1 Important Administration Information and adding the following statement: "Instruct patients or caregivers to use an oral dosing syringe to correctly measure the prescribed amount of medication. Inform patients that oral dosing syringes may be obtained from their pharmacy."
For parenteral products: include statement: *"Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."*[11]	N/A	
If there is a USP monograph for the drug product and it contains a labeling requirement, ensure the labeling requirement is fulfilled.[12] Note the labeling requirement may be applicable to another section of the PI (e.g., Section 11).	N/A	
For radioactive products, include radiation dosimetry for the patient and healthcare	N/A	

[10] Draft Guidance: Use of Liquids and/or Soft Foods as Vehicles for Drug Administration: General Considerations for Selection and In Vitro Methods for Product Quality Assessments
[11] §201.57(c)(3)(iv)
[12] USP General Notices 2.30 Legal Recognition

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments (If an item is Inadequate, provide more details on the issues, as appropriate)
practitioner(s) who administer the drug		
For hazardous products, include the statement *"DRUG X is a hazardous drug. Follow applicable special handling and disposal procedures.*[x]*"* with x numerical citation to "OSHA Hazardous Drugs."	N/A	

Assessment: *Adequate*

1) OPQ suggested creating a new Section 2.1 Important Administration Information and adding the following statement: "Instruct patients or caregivers to use an oral dosing syringe to correctly measure the prescribed amount of medication. Inform patients that oral dosing syringes may be obtained from their pharmacy." DMEPA concurred with this recommendation.

***Information request sent on October 29, 2025*:**

Comments were added to SharePoint link and an email was sent to the applicant as an attachment.

Review of Response Submitted in Amendment 14 Dated 19-Nov-2025

The applicant agreed to all recommendations and provided a revised package insert. The response is acceptable.

1.2.2 Section 3 (DOSAGE FORMS AND STRENGTHS)[13]

A copy of the PI submitted in original NDA (top picture from Amendment 4) and revised PI (bottom picture from Amendment 14) are reproduced below.

(b) (4)

[redacted]

[13] See § 201.57(c)(4); Labeling Review Tool (March 2022, page 29)

(b) (4)

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments (If an item is Inadequate, provide more details on the issues, as appropriate)
DOSAGE FORMS AND STRENGTHS section		
Available dosage form(s)	Adequate	
Strength(s) in metric system	Adequate	
If the active ingredient is a salt, apply the USP Salt Policy per FDA Guidance. Clearly state whether the strength is based on the active moiety (e.g., Tablets: 10 mg of drug-x) or active ingredient (e.g., Tablets: 10 mg of drug-x hydrochloride). No equivalency statement.	N/A	
A description of the identifying characteristics of the dosage forms, including shape, color, coating, scoring, imprinting, and color and clarity of the solution, when applicable.	Adequate	
Assess if the tablet is scored. If product meets guidelines and criteria for a scored tablet, state "functionally scored."	N/A	
For injectable drug products for parenteral administration, use appropriate package type term (e.g., single-dose, multiple-dose, single-patient-use). Other package type terms include pharmacy bulk package and imaging bulk package (see USP <659>).	N/A	

Assessment: *Adequate*

1.2.3 Section 11 (DESCRIPTION)[14]

A copy of the PI submitted in original NDA (top picture from Amendment 4) and revised PI (bottom picture from Amendment 14) are reproduced below.



[14] See § 201.57(c)(12); Labeling Review Tool (March 2022, page 56)

(b) (4)

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments (If an item is Inadequate, provide more details on the issues, as appropriate)
DESCRIPTION section		
Proprietary and established name(s)[15] [§ 201.57(c)(12)(i)(A)].	Adequate	

[15] Use of "USP" descriptor is not required to be included next to the established name throughout Prescribing Information (PI) labeling. If an applicant wants to use the "USP" descriptor next to the established name in the PI, recommend limiting its use to the product quality sections of the Full Prescribing Information (FPI)

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments (If an item is Inadequate, provide more details on the issues, as appropriate)
Dosage form(s) and route(s) of administration [§ 201.57(c)(12)(i)(B)].	Adequate	
If the active ingredient is a salt, apply the USP Salt Policy and include the equivalency statement per Salt Guidance and MAPP. For example: "TRADENAME contains 100 mg of drug-x (equivalent to 123.7 mg of drug-x hydrochloride)" [§ 201.57(c)(12)(i)(C)].	N/A	
List inactive ingredients (not required for oral use, except for colorant) by the USP/NF names in alphabetical order.[16] Avoid brand names. [§ 201.57(c)(12)(i)(C)].	Adequate	
For parenteral injectable dosage forms, include the name and quantities of all inactive ingredients. For ingredients added to adjust the pH or make isotonic, include the name and statement of effect. [§ 201.100(b)(5)(iii)].	N/A	
If alcohol is present, must provide the amount of alcohol in terms of percent volume of absolute alcohol at 60 °F. (15.56 °C) [§ 201.10(d)(2)].	N/A	
Sterility statement (if applicable) [§ 201.57(c)(12)(i)(D)].	N/A	

(i.e., DOSAGE FORMS AND STRENGTHS, DESCRIPTION, HOW SUPPLIED/STORAGE AND HANDLING) (see page 3 of LRT).

[16] Per § 201.100(b)(5)(i) and (ii), flavoring and colorants may be designated as such without naming their components except for FD&C Yellow No 5 and FD&C Yellow No 6, which must be listed per § 201.20. Per § 201.100(b)(5)(iii), trace amounts of harmless substances added solely for individual product identification need not be named. If an applicant wants to use the National Formulary (NF) descriptor next to excipients, recommend limiting its use to the product quality sections of the FPI (see page 3 of LRT). Do not list brand names, e.g., Opadry, Eudragit, Polistirex, etc.

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments (If an item is Inadequate, provide more details on the issues, as appropriate)
Pharmacological/Therapeutic class[17] [§ 201.57(c)(12)(i)(E)].	Adequate "(b) (4)"	
Chemical name[18], structural formula, molecular weight [§ 201.57(c)(12)(i)(F)].	Adequate	
If radioactive, statement of important nuclear characteristics [§ 201.57(c)(12)(i)(G)].	N/A	
Other important chemical or physical properties (such as pKa or pH) [201.57(c)(12)(ii)].	N/A	
For oral prescription drug products, include gluten statement[19] (if applicable).	N/A	
Remove statements that may be misleading or promotional (e.g., "synthesized and developed by Drug Company X," "structurally unique molecular entity").	N/A	
If there is a USP monograph for the drug product and it contains a labeling requirement, ensure the labeling requirement is fulfilled. Note the labeling requirement may be applicable to another section of the PI (e.g., Section 2).	N/A	

Assessment: *Adequate*

[17] Listed before "indicated for" in INDICATIONS AND USAGE of Highlights section [§ 201.57(a)(6)]; can also search the term "FDA EPC Text Phrases" in FDA's Labeling Resources for Human Prescription Drugs for the most recent EPC list.

[18] Chemical names do not need to be capitalized unless it appears at the beginning of a sentence (see *Preferred IUPAC Names Provisional Recommendation*, September 2004; Chapter 1, par. 16 Name writing, p.80-90).

[19] Draft guidance: *Gluten in Drug Products and Associated Labeling Recommendations* (December 2017)

1.2.4 Section 16 (HOW SUPPLIED/STORAGE AND HANDLING)[20]

A copy of the PI submitted in original NDA (top picture from Amendment 4) and revised PI (bottom picture from Amendment 14) are reproduced below.

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments (If an item is Inadequate, provide more details on the issues, as appropriate)
HOW SUPPLIED/STORAGE AND HANDLING section		
Available dosage form(s) [§ 201.57(c)(17)].	Adequate	
Strength(s) in metric system. [§ 201.57(c)(17)(i)] If the active ingredient is a salt, apply the USP Salt Policy per FDA Guidance. Clearly state whether the strength is based on the active moiety. No equivalency statement.	Adequate	
Available units (e.g., bottles of 100 tablets) [§ 201.57(c)(17)(ii)].	Adequate	
Identification of dosage forms (e.g., shape, color, coating, scoring, imprinting, and color and clarity of the solution, when	Adequate	

[20] See § 201.57(c)(17); Labeling Review Tool (March 2022, page 70). Consider including proprietary name and established name.

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments (If an item is Inadequate, provide more details on the issues, as appropriate)
applicable); Include NDC(s) [§ 201.57(c)(17)(iii)].		
Assess if the tablet is scored. If product meets guidelines and criteria for a scored tablet, state "functionally scored."	N/A	
For injectable drug products for parenteral administration, use appropriate package type term (e.g., single-dose, multiple-dose, single-patient-use). Other package terms include pharmacy bulk package and imaging bulk package (see USP <659>).	N/A	
Special handling about the supplied product (e.g., protect from light, refrigerate). If there is a statement to "Dispense in original container," provide reason why (e.g., to protect from light or moisture, to maintain stability, etc.). For hazardous drugs, state "DRUG X is a hazardous drug. Follow applicable special handling and disposal procedures.[x]" with x numerical citation to "OSHA Hazardous Drugs." [§ 201.57(c)(17)(iv)]	Inadequate	1) Revise the storage information in PI from [redacted (b) (4)] ." to "Store and dispense in the original container to protect from light." 2) Revised to include the discard statement for the in-use period of 30 days once the bottle is opened for use "Discard [redacted (b) (4)] 30 days after opening."
Storage conditions. Where applicable, use USP storage range rather than storage at a single temperature. (see USP <659>).	Adequate	
Latex: If product does not contain latex and manufacturing of product and container did not include use of natural rubber latex or synthetic derivatives of natural rubber latex, state: *"Not*	N/A	

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments (If an item is Inadequate, provide more details on the issues, as appropriate)
made with natural rubber latex. Avoid statements such as "latex-free."[21]		
Include information about child-resistant packaging[22] (if chosen by manufacturer).	Adequate	

Assessment: *Adequate*

2) OPQ suggested adding the discard statement "Discard (b) (4) 30 days after opening" for the drug product to Section 16 of the PI, and DMEPA concurred.
3) DMEPA suggested to revise the storage information in the Section 16 of PI from (b) (4)." to "Store and dispense in the original container to protect from light." OPQ concurred based on the results of the drug product stress studies (in-use, photostability, and freeze-thaw), the container closure system (CCS) properties, and the drug product stability data.

***Information request sent on October 29, 2025*:**

Comments were added to SharePoint link and email was sent to the applicant as attachment.

Review of Response Submitted in Amendment 14 Dated 19-Nov-2025

The applicant agreed to all recommendations and provided a revised package insert. The applicant's response is acceptable.

1.2.5 Other Sections of Labeling: None

[21] Guidance: *Recommendations for Labeling Medical Products to Inform Users that the Product or Product Container is not Made with Natural Rubber Latex* (December 2014)
[22] Guidance: *Child-Resistant Packaging Statements in Drug Product Labeling* (August 2019)

1.2.6 Manufacturing Information After Section 17 (for drug products)[23]

A copy of the PI reproduced from Amendment 14

(b) (4)

Item	Item in Proposed Labeling (choose "Adequate" or "Inadequate")	Assessor's Comments (If an item is Inadequate, provide more details on the issues, as appropriate)
Manufacturing Information After Section 17		
Name and location of business (street address, city, state, and zip code) of the manufacturer, distributor, and/or packer.	Adequate	

Assessment: *Adequate*

2.0 PATIENT LABELING:

Assessment of Product Quality Related Aspects of Patient Labeling (e.g., Medication Guides, Instructions for Use, Patient Information):

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments about Labeling (If an item is Inadequate, provide more details on the issues, as appropriate)
Established name[24]	N/A	
Special preparation instructions (if applicable).	N/A	
Storage and handling information (if applicable).	N/A	
If the product contains a desiccant, ensure the desiccant has a warning (e.g., "Do not eat.") and the size and shape of the desiccant differ from the dosage form.	N/A	
Active ingredient(s) (if applicable).	N/A	

[23] § 201.1(h)(5) and 201.1(i); Labeling Review Tool (March 2022, page 74)
[24] Established name = [Drug] [Route of Administration] [Dosage Form]

Item	Item in Proposed Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments about Labeling (If an item is Inadequate, provide more details on the issues, as appropriate)
Alphabetical listing of inactive ingredients (if applicable).	N/A	
Name and location of business (street address, city, state, and zip code) of manufacturer, distributor, and/or packer.	N/A	

Assessment: N/A

3.0 CONTAINER AND CARTON LABELING[25]

3.1 Container Labels[26]

A copy of the container label submitted in original NDA (top picture from Amendment 1), revised container label with track changes (middle picture from Amendment 11) and final container labeling (bottom picture from Amendment 14) are reproduced below.

[25] Carton and Container Labeling Resources

[26] Per § 201.10(h)(2)(i)(1), if the drug container is too small to bear all labeling information required by section 502(e)(1)(A)(ii) and (B) of the FD&C Act, the container label should bear: proprietary name, established name, lot number, the name of the manufacturer, packer, or distributor of the drug.

(b) (4)



3.2 Carton Labeling: There is no carton.

Item	Item in Proposed Container Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments about Container Labels and Carton Labeling (If an item is Inadequate or different, provide more details, as appropriate)
Proprietary name and established name[27], (font size and prominence) [§ 201.10(g)(2)].	Adequate	
Strength(s) in metric system [§ 201.100(b)(4) & 201.100(d)].[28]	Adequate	
Route(s) of administration, not required for oral use [§ 201.100(b)(3)].	Adequate	
If the active ingredient is a salt, include the equivalency statement per Salt Guidance and MAPP [§ 201.10(d)(1) & 201.100(b)(4), USP <1121>].	N/A	
Net contents (e.g., tablet count, volume of liquid) [§ 201.51(a)].[29]	Adequate	
"Rx only" displayed on the principal display [§ 201.100(b)(1)].	Adequate	
NDC (requested, but not required for all labels or labeling) [§ 201.2 & 207.35].	Adequate	
Lot number and expiration date [§ 201.18 & 201.17].	Adequate	
Storage conditions. If applicable, include a space on the carton labeling for the user to write the beyond-use-date (BUD).	Inadequate	1) Revise the storage information in container labels from "(b) (4) [redacted]" to "Store and dispense in the original

[27] Established name = [Drug] [Route of Administration] [Dosage Form]

[28] Express as " XX mg per tablet" or "XX mg per capsule" for strength of professional samples of solid oral dosage form with small net quantities per container (e.g., 5 or less) or blister pack/carton. See Guidance: *Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors* (May 2022)

[29] § 201.51(h): A drug shall be exempt from compliance with the net quantity declaration required by this section if it is an ointment labeled "sample", "physician's sample", or a substantially similar statement and the contents of the package do not exceed 8 grams.

Item	Item in Proposed Container Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments about Container Labels and Carton Labeling (If an item is Inadequate or different, provide more details, as appropriate)
		container to protect from light." 2) Revised to include the discard statement for the in-use period of 30 days once the bottle is opened for use "Discard (b) (4) 30 days after opening."
For injectable drug products for parenteral administration, use appropriate package type term (e.g., single-dose, multiple-dose, single-patient-use). Other package terms include pharmacy bulk package and imaging bulk package, and these products require a "Not for direct infusion" statement. (See USP <659>).	N/A	
Name of all inactive ingredients, in alphabetical order [§ 201.10(a)] [except for oral drug per § 201.100(b)(5) or limited space per § 201.10(i)(2)].	N/A	
For parenteral injectable dosage forms, include quantities of all inactive ingredients. For ingredients added to adjust the pH or make isotonic, include the name and statement of effect. [§ 201.100(b)(5)(iii)].	N/A	
If alcohol is present, must provide the amount of alcohol in terms of percent volume of absolute alcohol at 60 °F. (15.56 °C) [§ 201.10(d)(2)].	N/A	

Item	Item in Proposed Container Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments about Container Labels and Carton Labeling (If an item is Inadequate or different, provide more details, as appropriate)
Linear Bar code [§ 201.25(c)(2)].[30]	Adequate	
Adequate directions for use: "Recommended Dosage: See Prescribing Information" [§ 201.5 & 201.55].	Adequate	
Name of manufacturer/distributor /packer [§ 201.1(a), 201.1(h)(5)].	Adequate	
"Keep out of reach of children" statement, optional for Rx, required for OTC [§ 201.66(c)(5)(x)].	Adequate	
If there is a Medication Guide, must include a statement about dispensing a Medication Guide to each patient.	N/A	
No text on Ferrule and Cap overseal of a vial of injectable products unless a cautionary statement is required. (USP <7>).	N/A	
If there is a USP monograph for the drug product and it contains a labeling requirement, ensure the labeling requirement is fulfilled.	N/A	
When a drug product differs from the relevant USP standard of strength, quality, or purity, as determined by the application of the tests, procedures, and acceptance criteria set forth in the relevant	N/A	

[30] See § 201.25(b)(1)(i) for a list where bar code is not required, e.g., prescription drug samples, medical gases, radiopharmaceuticals, etc.

Item	Item in Proposed Container Labeling (choose "Adequate", "Inadequate", or "N/A")	Assessor's Comments about Container Labels and Carton Labeling (If an item is Inadequate or different, provide more details, as appropriate)
compendium, its difference shall be plainly stated on its label.[31]		
And others if space is available.	N/A	

Assessment of Carton Labels and Container Labeling: *Adequate*

1) OPQ suggested adding the discard statement "Discard (b) (4) 30 days after opening" for the drug product on the container labels, and DMEPA concurred.
2) DMEPA suggested to revise the storage information on the labels and labeling from "(b) (4)." to "Store and dispense in the original container to protect from light." OPQ concurred based on the results of the drug product stress studies (in-use, photostability, and freeze-thaw), the container closure system (CCS) properties, and the drug product stability data.

***Information request sent on November 4, 2025*:**

The Office of Pharmaceutical Quality (OPQ) has determined that the proposed product is stable up to 30 days after opening the bottle. We recommend including the discard statement and space for end-users to write the beyond-use date on the container label after the statement "Store and dispense in the original container to protect from light." For example: Discard unused portion 30 days after first opening.

Discard after: ___/____/____

In addition, consider changing the color of the font, surrounding this information with a box, and/or highlighting the information to draw attention to this important information.

Review of Response Submitted in Amendment 14 Dated 19-Nov-2025

The Applicant made all recommended changes and provided the revised container labels. The applicant's response is acceptable.

[31] USP General Notices 3.20 Indicating Conformance

4. OUTSTANDING ISSUES AND RECOMMENDATIONS

None

Primary Drug Product Assessor Name and Date: Parvin Akther, CMC Reviewer, Unit 2/DPQAII/OPQAI/OPQ

Secondary Assessor Name and Date (and Secondary Summary, as needed): Richard Matsuoka, Ph.D., SPQA, Unit 2/DPQAII/OPQAI/OPQ

Parvin Akther

Digitally signed by Parvin Akther
Date: 12/09/2025 12:17:43PM
GUID: 633f09c00044efa5527a2ebac9c742a8
Comments: No change in Quality labeling review. MS word docm file has been converted to MS word docx to enable archiving as pdf.

Richard Matsuoka

Digitally signed by Richard Matsuoka
Date: 12/09/2025 12:22:21PM
GUID: 58405a2d00b8e6d18c2b669521269752

32 Page(s) have been Withheld in Full as B4 (CCI/TS) immediately following this page

CHAPTER VII: MICROBIOLOGY

IQA NDA Assessment Guide Reference

Product Information	
NDA Number	216395
Assessment Cycle Number	1
Drug Product Name/ Strength	QUIOFIC (Folic Acid) Oral Solution, 1 mg/5 mL
Route of Administration	Oral
Applicant Name	CMP Development LLC
Therapeutic Classification/ OND Division	Treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or non-tropical sprue) and in anemias of nutritional origin, pregnancy, infancy or childhood / Office of Cardiology, Hematology, Endocrinology and Nephrology - Division of Non-Malignant Hematology
Manufacturing Site	CMP Pharma, Inc. 8026 East Marlboro Road Farmville, NC 27828 FEI: 1050589
Method of Sterilization	N/A, drug product is non-sterile

Assessment Recommendation: **Adequate**

Assessment Summary: This is a multi-dose non-sterile oral drug product. (b) (4) [redacted] Supporting data meet the quality microbiology review criteria.

List Submissions being assessed (table):

Document(s) Assessed	Date Received
ORIG-1 (SN 0001-0003)	03/26/2025
IR response (Seq-0006, SDN6)	06/10/2025

Highlight Key Issues from Last Cycle and Their Resolution: N/A

Remarks: The drug product is an oral Solution: 1 mg/5 mL. It is a yellow solution with a mixed berry flavor packaged in a bottle with a child-resistant cap. The drug product is indicated in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood.

Concise Description of Outstanding Issues: None.

Supporting Documents: N/A

S DRUG SUBSTANCE – not assessed due to low microbiological risk for this liquid oral nonsterile drug product.

P.1 DESCRIPTION OF THE COMPOSITION OF THE DRUG PRODUCT

- **Description of drug product –** Section 3.2.P.1., pg. 1
  Folic Acid Oral Solution 1mg/5mL is a yellow solution (b) (4) in an amber bottle with a child-proof cap.

- **Drug product composition –** Section 3.2.P.1, pg. 3-4

Ingredient	Quantity (mg per 5mL)	Function
Folic Acid USP	1	API
Sodium Phosphate Monobasic, (b) (4) USP	(b) (4)	
Sodium Phosphate Dibasic, (b) (4) USP		
Propylene Glycol USP		
Edetate Disodium USP		
Methylparaben NF		
Propylparaben NF		
Sorbitol Solution (b) (4) USP		
Mixed Berry Flavor, (b) (4)		
Purified Water USP		

- **Description of container closure system –** Section 3.2.P.1 pg. 7 and P.7

Component	Description	Manufacturer
(b) (4) Bottle	(b) (4) Round, Amber, PETE Bottle	(b) (4)
24 mm Child Resistant (CR) Closure Round, white outer cap with clear plastic inner closure with heat induction seal	Closure, White (b) (4)	

Assessment: *Adequate*
The applicant has provided a sufficient description of the drug product composition and container closure system.

11 Page(s) have been Withheld in Full as B4 (CCI/TS) immediately following this page

---

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

RICHARD T MATSUOKA
12/10/2025 06:12:00 PM